钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病管理中的作用。
The role of SGLT2 inhibitors in managing type 2 diabetes.
作者信息
Tat Velen, Forest Christopher P
机构信息
Velen Tat is a PA fellow in the ED of Arrowhead Regional Medical Center in Colton, Calif. The author began this article while a student in the Primary Care PA Program at the University of Southern California's Keck School of Medicine in Alhambra, Calif. Christopher P. Forest is a professor of health science and human services at California State University Monterey Bay and founding program director of the Master of Science PA program. The authors have disclosed no potential conflicts of interest, financial or otherwise.
出版信息
JAAPA. 2018 Jun;31(6):35-40. doi: 10.1097/01.JAA.0000533660.86287.04.
The sodium glucose cotransporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin represent a novel class of medications to manage type 2 diabetes through urinary excretion of glucose. These drugs block glucose reabsorption by the kidneys to increase glucosuria. These drugs provide hemoglobin A1C reduction, promote weight loss, and remain hypoglycemic-neutral when not used in combination with insulin or secretagogues. Canagliflozin and empagliflozin have shown cardiovascular benefit. The potential to reduce the risk of cardiovascular death in patients with type 2 diabetes, along with the benefit of weight reduction, makes these new agents useful tools for the primary care provider.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂卡格列净、达格列净、恩格列净和依鲁格列净是一类新型药物，可通过促进尿糖排泄来治疗2型糖尿病。这些药物可阻断肾脏对葡萄糖的重吸收，从而增加糖尿。这些药物可降低糖化血红蛋白水平，促进体重减轻，在不与胰岛素或促分泌剂联合使用时不会引起低血糖。卡格列净和恩格列净已显示出心血管益处。降低2型糖尿病患者心血管死亡风险的潜力，以及减轻体重的益处，使这些新型药物成为初级保健提供者的有用工具。
Zotero 插件